Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
In the last reported quarter, the company's adjusted earnings per share of 64 cents beat the Zacks Consensus Estimate by 6.67%. Its earnings beat estimates in two of the trailing four quarters and matched on the other two occasions, the average surprise being 3.49%.
Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.49 billion, suggesting an 8.9% decline from the year-ago reported figure.
The Zacks Consensus Estimate for net earnings of 62 cents per share indicates an 11.4% decline from the year-ago reported figure.
Estimate Revision Trend Ahead of Edwards' Q2 Earnings
Estimates for earnings have remained unchanged at 62 cents per share in the past 60 days.
Here's a brief overview of the company's progress ahead of this announcement.
Factors at Play
In the second quarter of 2025, the Transcatheter Aortic Valve Replacement ('TAVR') arm is likely to have delivered a strong performance in the United States, thanks to its market-leading SAPIEN 3 Ultra RESILIA platform. The continued expansion of SAPIEN3 Ultra RESILIA in Europe is expected to have supported the international performance. The platform has demonstrated remarkable patient outcomes, and the momentum is expected to have continued with more centers adopting it. Although we expect the company to have endured a weak procedure growth environment and competitive pressure in Japan, it remained dedicated to addressing significant undertreatment of aortic stenosis among the country's substantial elderly population.
On its previous earnings call, Edwards stated that it experienced a few instances of regional variability despite holding a strong competitive position and stable global pricing. The trend is likely to have continued in the second quarter, restricting the segment's full potential. Our model assumes TAVR sales to be $1.09 billion, implying a 5.2% year-over-year increase.
In the Transcatheter Mitral and Tricuspid Therapies ('TMTT') segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards' performance in second-quarter 2025. The PASCAL repair system is expected to have gained traction in the United States, Europe and globally, thanks to its differentiated features, leading to increased adoption of the technology at both existing and new centers.
Additionally, the commercial launch of the EVOQUE tricuspid replacement system might have continued to progress in the United States and Europe. As of March, it gained Medicare coverage under the finalized NCD for transcatheter tricuspid valve replacement, expanding access.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote
Edwards has raised its 2025 sales guidance for this segment to $530-$550 million (earlier $500 million), and we expect the company to have progressed meaningfully in the to-be-reported quarter. Our model estimates the TMTT business to report revenues of $130.4 million, implying a 57.1% improvement from the year-ago period's level.
Lastly, Edwards' Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT. The company likely saw positive procedural growth globally for the many patients best treated surgically, including complex and concomitant procedures. Furthermore, MITRIS' launch in China with positive surgeon feedback might have contributed to the second-quarter top line.
Our model estimates the segment's revenues to be $263.1 million, suggesting a modest 6.2% rise from the year-ago quarter's reported figure.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle:
CVS Health CVS has an Earnings ESP of +2.06% and a Zacks Rank #1 at present. The company is slated to release second-quarter 2025 results on July 31. You can see the complete list of today's Zacks #1 Rank stocks here.
CVS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.08%. The Zacks Consensus Estimate for second-quarter EPS implies a year-over-year decline of 19.7%.
Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6.
The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%.
Cardinal Health CAH has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12.
CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
21 minutes ago
- Globe and Mail
Wolverine Worldwide Announces Second Quarter Fiscal 2025 Conference Call for August 6, 2025
Wolverine World Wide, Inc. (NYSE: WWW) today announced that it expects to report its second quarter fiscal 2025 financial results on Wednesday, August 6, 2025, at approximately 6:30 a.m. ET. Following the press release, the Company will host a conference call at 8:30 a.m. ET to review results and discuss current business trends. Investors and analysts interested in joining the call are invited to dial 1-800-715-9871 (international callers, please dial 1-646-307-1963) approximately five minutes prior to the start of the call. The conference call will be broadcast live and accessible under 'Webcasts & Presentations' in the Investor Relations section of A recorded replay of the call will be available shortly after the conclusion of the call and remain available until August 13, 2025. To access the telephone replay, dial 1-800-770-2030 (international callers, please dial 1-609-800-9909). The access code for the replay is 9927992. ABOUT WOLVERINE WORLDWIDE Founded in 1883, Wolverine World Wide, Inc. (NYSE:WWW) is one of the world's leading designers, marketers, and licensors of branded casual footwear and apparel, performance outdoor and athletic footwear and apparel, kids' footwear, industrial work boots and apparel, and uniform footwear. The Company's portfolio includes Merrell®, Saucony®, Sweaty Betty®, Hush Puppies®, Wolverine®, Chaco®, Bates®, HYTEST®, and Stride Rite®. Wolverine Worldwide is also the global footwear licensee of the popular brands Cat® and Harley-Davidson®. Based in Rockford, Michigan, for more than 140 years, the Company's products are carried by leading retailers in the U.S. and globally in approximately 170 countries and territories. Wolverine Worldwide is a Great Place to Work® Certified™ company. For additional information, please visit our website,
Globe and Mail
21 minutes ago
- Globe and Mail
Spectrum Brands Holdings to Report Fiscal 2025 Third Quarter Financial Results and Hold Conference Call and Webcast on August 7, 2025
Spectrum Brands Holdings, Inc. (NYSE: SPB; 'Spectrum Brands'), a leading global branded consumer products and home essentials company focused on driving innovation and providing exceptional customer service, announced today it will release its fiscal 2025 third quarter financial results for the period ended June 29, 2025 before the markets open on Thursday, August 7, 2025. Spectrum Brands will conduct a live conference call and live webcast on August 7, 2025 at 9:00 a.m. Eastern Time (8:00 a.m. Central Time), which will be hosted by David Maura, Executive Chairman and Chief Executive Officer, and Jeremy Smeltser, Executive Vice President and Chief Financial Officer. The live webcast and related presentation slides will be available by visiting the Event Calendar page in the Investor Relations section of Spectrum Brands' website at Participants may register for the call here. Instructions will be provided to ensure the necessary audio applications are downloaded and installed. Users can obtain these at no charge. Following the call, a replay of the live broadcast also will be accessible through the Event Calendar page in the Investor Relations section of Spectrum Brands' website. About Spectrum Brands Holdings, Inc. Spectrum Brands is a home-essentials company with a mission to make living better at home. We focus on delivering innovative products and solutions to consumers for use in and around the home through our trusted brands. We are a leading supplier of specialty pet supplies, lawn and garden and home pest control products, personal insect repellents, shaving and grooming products, personal care products, and small household appliances. Helping to meet the needs of consumers worldwide, we offer a broad portfolio of market-leading, well-known and widely trusted brands including Tetra®, DreamBone®, SmartBones®, Nature's Miracle®, 8-in-1®, FURminator®, Healthy-Hide®, Good Boy®, Meowee!®, OmegaOne®, Spectracide®, Cutter®, Repel®, Hot Shot®, Rejuvenate®, Black Flag®, Liquid Fence®, Remington®, George Foreman®, Russell Hobbs®, BLACK + DECKER®, PowerXL®, Emeril Lagasse®, and Copper Chef®. For more information, please visit Spectrum Brands – A Home Essentials Company™.
Globe and Mail
21 minutes ago
- Globe and Mail
NANO Nuclear Completes Assembly of Its Proprietary Annular Linear Induction Pump Technology Prototype for Critical Test Loop Validation In SBIR Phase III Program
Milestone demonstrates NANO Nuclear's ability to bring advanced nuclear technology from initial design to construction and demonstration New York, New York--(Newsfile Corp. - July 23, 2025) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that its proprietary, patent pending Annular Linear Induction Pump (ALIP) technology for nuclear reactors has been assembled onto a test loop and integrated to a controllable test setup for variable design validation at NANO Nuclear's Demonstration Facility in Westchester County, New York. As NANO Nuclear continues progress with its microreactor programs, including its lead KRONOS MMR TM Energy System project, the ALIP assembly milestone demonstrates NANO Nuclear's leadership in advanced nuclear energy technology and its ability to move technology from initial design to construction and demonstration. NANO Nuclear hopes to be able to start commercial sales activities for ALIP by the end of this year or next year. This milestone also underscores the utility of NANO Nuclear's Westchester Demonstration Facility, which became operational earlier this year. "This initial milestone with ALIP shows in a small but very promising way what we can do as a company in the real world," said James Walker, Chief Executive Officer of NANO Nuclear. "ALIP is an enabling technology that supports the development of next-generation reactors utilizing molten salts or liquid metals, and advancing ALIP through the SBIR Phase III process has allowed us to mature the system extensively, refining its design, validating key performance metrics, and preparing it for integration into demonstration-scale platforms at our custom-built Westchester facility. This progress not only enhances the technology's readiness for deployment but also opens a clear pathway toward revenue generating activities for NANO Nuclear as we progress work on our broader portfolio of advanced nuclear technologies." The ALIP technology is a thermal management and distribution system within NANO Nuclear's suite of advanced nuclear energy technologies. It operates using electromagnetic, in place of mechanical, pumps, and could serve as a critical component in the development of advanced molten-salt and liquid-metal nuclear reactors. As previously announced, earlier this year, NANO Nuclear collaborated with aRobotics Company, a leading innovator in robotics fabrication, inspection, engineering and testing, to support NANO Nuclear's ongoing SBIR Phase III program for ALIP, which was previously funded by the U.S Department of Energy. Data from the test and validation work being done will be leveraged to support the SBIR Phase III program. Figure 1 - NANO Nuclear Energy 's ALIP Technology (center) integrated on the Test Loop inside Custom-Engineered Thermal Chamber at the Demonstration Facility in Westchester County, New York. To view an enhanced version of this graphic, please visit: "Developing the first iteration of NANO Nuclear's ALIP and its adjacent test instrumentation enables us to collect crucial data and advance this project towards its ultimate goal of commercialization," said Jay Yu, Founder and Chairman of NANO Nuclear. "With the support of aRobotics Company, we plan to steadily develop and test additional generations of ALIP as we improve the technology's readiness for the market." To view an enhanced version of this graphic, please visit: "We believe ALIP will have a number of applications upon development including in the space and defense sectors," said Akaash Kancharla, CEO of aRobotics Company. "The procedural knowledge and material science advanced by this work will have implications far beyond this useful product." By utilizing a time-varying magnetic field, ALIPs enable the movement of conductive fluids without mechanical components, reducing wear and maintenance requirements while increasing efficiency. Current efforts at the NANO Nuclear Demonstration Facility are geared towards the development of the first operational ALIP prototype and a custom designed test loop for research data collection, alongside a magnetic field mapping system, for the collection of manufacturing and performance data. Future work will include testing and characterizing pump performance with different working fluids, simulating component failure scenarios, and material testing. To view an enhanced version of this graphic, please visit: About NANO Nuclear Energy Inc. NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S. Led by a world-class nuclear engineering team, NANO Nuclear's reactor products in development include patented KRONOS MMR ™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign (U. of I.), " ZEUS", a solid core battery reactor, and " ODIN", a low-pressure coolant reactor, and the space focused, portable LOKI MMR ™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors. Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, is led by former executives from the largest transportation company in the world aiming to build a North American transportation company that will provide commercial quantities of HALEU fuel to small modular reactors, microreactor companies, national laboratories, military, and DOE programs. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. Assuming development and commercialization, AFT is expected to form part of the only vertically integrated nuclear fuel business of its kind in North America. HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry. NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear's developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR ™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS' initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface. For more corporate information, please visit: For further NANO Nuclear information, please contact: Email: IR@ Business Tel: (212) 634-9206 PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE: NANO Nuclear Energy LINKEDIN NANO Nuclear Energy YOUTUBE NANO Nuclear Energy X PLATFORM Cautionary Note Regarding Forward-Looking Statements This news release and statements of NANO Nuclear's management and collaborators in connection with this news release contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "potential", "will", "should", "could", "would," "seek," "hope, "may" and other words of similar meaning. In this press release, forward-looking statements include those related to NANO Nuclear's development and commercialization plans for the ALIP technology. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy ("DOE") or related state or non-U.S. nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complimentary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain contracts and funding to be able to continue operations, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE and the U.S. Nuclear Regulatory Commission, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating an early stage business a highly regulated and rapidly evolving industry. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at and at Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
